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Summary Cyclin E is a G, cyclin that is essential for the transition from G, to S phase in the cell cycle. Alterations to cyclin E expression or
regulation could be important in tumorigenesis. Previous immunohistochemical and immunoblotting studies have investigated the expression
of cyclin E in breast carcinomas. In this study, cyclin E has been investigated in a range of non-malignant and malignant breasj using
immunohistochemistry. Normal and benign tissue from pre- and post-menopausal women (39 cases), non-involved tissue from cancer-
containing breasts (47 cases), ductal carcinoma in situ (22 cases) and invasive breast carcinomas (109 cases) have been examined. There
was no reactivity in any of the non-malignant breast. Only one ductal carcinoma in situ contained more than 5% reactive cells. A total of 28%
of invasive carcinomas had > 5% of reactive cells (range 0-88% positive cells, mean 12.59%, median 1.0%). A significant association was
found with poorer differentiation (P < 0.001), high MIBl index (P < 0.001), lack of oestrogen receptor (0.05 > P > 0.025) and the presence of
p53 protein (0.05 > P > 0.025). Virtually all cases with cyclin E and p53 were poorly differentiated. The presence of cyclin E is therefore only
found in breast malignancies and is associated with more aggressive features, including high proliferation.
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The cell cycle is the ordered set of processes by which one cell
grows and divides into two daughter cells (Murray and Hunt,
1993). This process is the basis for the continuity of life and
underlies the complexity ofgrowth, renewal andrepair active in all
multicellular organisms. Over the last two decades, our knowledge
of the complex machinery which regulates the cell cycle has
dramatically increased; in particular, the links between onco-
genesis and the cell cycle components.
Transition through the different phases of the cell cycle is
achieved by the formation and inhibition of enzymatically active
protein complexes composed of cyclins and their regulatory
subunits, the cyclin-dependent kinases (CDKs) (Hunter and Pines,
1994). Among theGI cyclins, cyclin E appears to be essential for
the G1/S transition as inhibition ofthe function ofcyclin E and its
related cyclin-dependent kinase, cdk2, prevents mammalian cells
from entering S phase (Pagano et al, 1993; Tsai et al, 1993;
Ohtsubo et al, 1995). The cyclin E protein level peaks in late GI
(Dulic et al, 1992; Koff et al, 1992), which correlates with the
phosphorylation ofpRb, the product ofthe retinoblastoma tumour
suppressor gene. pRb plays a critical role in the cell cycle as its
phosphorylation leads to the liberation ofcertain bound transcrip-
tion factors essential for DNA synthesis (Nevins, 1992; La
Thangue, 1994). The importance of cyclin E in the cell cycle
suggests that it is a potential target in tumorigenesis.
In the search for newer markers which can provide information
about breast cancer behaviour, attention has recently focused on
the role of cyclin E. Previous studies have demonstrated that
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overexpression correlates with tumour aggressiveness (Keyomarsi
et al, 1994; Nielsen et al, 1996). These studies investigated expres-
sion using Western blotting. Although this will provide information
about different molecular weight isoforms, it restricts the spectrum
of breast carcinomas that can be investigated as it requires large
amounts offresh tissue. Dutta et al (1995) used immunohistochem-
istry and showed in 48 breast cancers that there was a correlation
between expression and tumour proliferation. Immunohisto-
chemistry has the advantage ofbeing applicable to a wide range of
material, including benign, non-invasive and invasive carcinomas of
all sizes. We have therefore used this approach to investigate the
role of cyclin E in both development and progression of breast
cancer, by examining expression in a wide range of, tissues in
normal, hyperplastic, non-invasive and invasive breast tissues.
MATERIALS AND METHODS
Tissues
All breast tissue was received fresh within 20 min of surgical exci-
sion. Representative blocks were taken and fixed in 4% formalde-
hyde in saline for 18 h, routinely processed andparaffin embedded.
Surgical excision of the 109 invasive breast carcinomas and 22
ductal carcinomas in situ took place at the Glenfield Hospital,
Leicester, in the period from 1992 to 1996. For 47 cases, samples
were taken of non-involved tissue at least 4 cm away from the
carcinoma, fixed and processed as before. The age range of the
patients with carcinomas was 27-64 years, and for patients from
whom non-involved tissue was also taken 27-58 years. Routine
histopathological analysis was carried out on H & E sections by
RAW and all carcinomas classified using guidelines for pathology
reporting in breast cancer screening (1995) and graded using a
modified Bloom and Richardson method (Elston and Ellis, 1991).
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Figure 1 High-grade ductal carcinoma in situ in which many of the cells
within this individual duct show nuclear staining for cyclin E
Table 1 Relationship between the nuclear grade of ductal carcinoma in situ
and cyclin E expression
Nuclear grade < 1% staining 1-5% staining > 5% staining
Low 8 0 0
Intermediate 0 3 0
High 5 5 1
Normal and benign tissue from 39 cases, which had been fixed
and processed in a similar way, were also studied. The tissues were
assessed histologically for the extent of any benign change. The
age range ofthe patients was 32-64 years.
Antibodies
The following were used: mouse monoclonal antibody against
cyclin E (HE12) generated against recombinant human cyclin E
protein (Santa Cruz), as used by Dutta et al (1995). (In
immunoblotting it recognizes the major human cyclin E-encoded
proteins as three bands including a doublet at around 50 kDa and a
single band at 42 kDa.) MIB-1 mouse monoclonal antibody
against the Ki-67 antigen (Cattoretti et al, 1992) (The Binding
Site); polyclonal rabbit anti p53 antiserum (CM1) from Novo
Castra. All secondary reagents were from Dako UK.
Immunohistochemistry
MIB-1
Formalin-fixed, paraffin-embedded sections were mounted on
slides coated with silane (3-aminopropyltriethoxysilane, BDH)
and immersed in 10 mm citric acid buffer, pH 6.0. The sections
were then exposed to pressure cooking for 1 min (Norton, 1994).
MIB-1 antibody in 20% normal rabbit serum was applied in a
1:100 dilution for 1 h at room temperature. Biotinylated rabbit
anti-mouse immunoglobulin antiserum followed by streptavidin-
peroxidase was the detection system, andperoxidase was localized
using diaminobenzidine-hydrogen peroxide.
Figure 2 Infiltrating ductal carcinoma in which many of the cells show
nuclear staining for cyclin E
Cyclin Eandp53
For the detection of cyclin E and p53, sections were immersed in
10 mm citric acidbuffer, pH 6.0, andexposed to twocycles, each of
5 min, of microwaving using an 800-W microwave at full power.
The antibodies were applied as follows: cyclin E at 1:50 for 4 h at
room temperature; CM1 at 1:800 overnight at 4°C. Cyclin E was
detected using biotinylated rabbit anti-mouse immunoglobulin
antiserum and CM1 using biotinylated swine anti-rabbit immuno-
globulin antiserum followedby streptavidin-peroxidase complex as
above and diaminobenzidine-hydrogen peroxide detection.
Controls in all instances were the omission of the primary
antibody and the inclusion of a known positive with each staining
batch.
Oestrogen and progesterone receptor determination
Information about the oestrogen andprogesterone receptorcontent
in the carcinoma specimens was available. This was determined
using the antibodies 1D5 and NCL-PgR on fixed tissue as
previously described (Rajakariar and Walker, 1995). These were
evaluated by RAW.
Evaluation
Carcinomas
For the invasive carcinomas, approximately 1000 nuclei were
counted taking into consideration the heterogeneity across the
tumoursection. The carcinomas werethen categorized on the basis
of the percentage of nuclear staining. Carcinomas were deter-
mined positive for cyclin E if more than 5% of cells exhibited
moderate or strong staining. This value was chosen after exam-
ining the relationship of different cut-off points (1%, 5%, 10%,
20%) to the different parameters, as it gave the greatest signifi-
cance. The MIB-1 index was considered low with less than 10%
staining, moderate with staining between 10% and 20%, and high
ifgreater than 20% staining. Forp53, carcinomas with greaterthan
20% of cells with moderate or strong staining were considered
positive (Isola et al, 1992).
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Figure 3 Infiltrating ductal carcinoma that has scattered nuclei expressing
cyclin E
Ductal carcinoma in situ
Ten ducts were selected for each case and the proportion ofnuclei
reacting categorized into three groups as follows: < 1%, 1-5%,
> 5% ofnuclei stained.
Normal and surround breast tissue
When possible, ten lobules and ten ducts were selected from each
tissue and 1000 nuclei counted from both to give a simple
percentage ofstaining for acini and ducts.
Statistics
Comparison ofdifferent groups was by X2 or Fisher's exact proba-
bility (two-tail) test. Comparison of two means was performed by
the Student's t-test. Comparison of several means was performed
by the one-way analysis ofvariance.
RESULTS
Cyclin E in non-malignant breast
No cyclin E immunoreactivity was observed in any of normal or
benign tissue examined, including non-involved tissue from
cancer-containing breasts.
Cyclin E in ductal carcinoma in situ
There were 22 cases ofductal carcinoma in situ (DCIS). These were
categorized as 11 cases of high nuclear grade, three ofintermediate
nuclear grade and eight of low nuclear grade. The proportion of
nuclei stained varied greatly between ducts in the same section and
was therefore difficult to analyse. In addition, the nuclear staining
intensity was often heterogeneous within individual ducts and ranged
between weak and strong (Figure 1). A formal statistical analysis
could notbeperformed owing to the small numberofcases examined
(Table 1). However the low-grade cases had a lower incidence of
reactivity, with no tumours having > 1% cells with nuclear staining.
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Figure 4 Distribution of reactivity for cyclin E amongst the carcinomas
studied
Table 2 Relationship between cyclin E expression and biological and
clinical variables in invasive carcinomas.
Low cyclin E High cyclin E
expression expression
(number of tumours) (number oftumours)
Lymph node status
No evidence of metastasis 36.7% (40) 13.8% (15)
Metastasis 34.8% (38) 14.7% (16)
Grade
Well-differentiated (I) 18.3% (20) 0.9% (1)
Moderately differentiated (II) 33.0% (36) 5.6% (6)
Poorly differentiated (III) 20.2% (22) 22.0% (24)
Oestrogen receptor
Negative 19.2% (19) 16.2% (16)
Positive 50.5% (50) 14.1% (14)
MIBl expression
Low 39.4% (43) 4.6% (5)
Medium 19.3% (21) 4.6% (5)
High 12.8% (14) 19.3% (21)
p53
Negative 60.5% (66) 18.5% (20)
Positive 11.0% (12) 10.0% (11)
Expression of cyclin E in invasive carcinomas
Staining for cyclin E was predominantly nuclear, although rarely
there was associated cytoplasmic staining. Reactivity was predom-
inantly moderate or strong in intensity and only nuclei that were
clearly positive were considered for evaluation (Figures 2 and 3).
Cyclin E staining was variable and heterogeneous in 86 (79%)
carcinomas, and 23 (21%) showed no immunoreactivity. The
percentage of cyclin E reactive nuclei ranged from 0 to 88% of
tumourcells, with a mean of 12.59 and a median of 1%. Thirty-one
(28%) cases showed cyclin E immunoreactivity in more than 5%
of tumour cells and were considered to express high levels of
cyclin E (Figure 4).
The relationship between cyclin E expression and tumour
characteristics are shown in Table 2. There were 93 infiltrating
ductal carcinomas, ten infiltrating lobular carcinomas, six tubular
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carcinomas and one mucinous carcinoma. There was no relation-
ship between cyclin Eexpression and type, cyclin Ebeing present
in both infiltrating ductal and lobular carcinomas, although not
tubular carcinomas. There was a significant relationship between
cyclin E and histological grade (X2 = 22.65, 2 d.f., P < 0.001). A
high cyclin E index was associated with poorer differentiation.
There was norelationship betweencyclin Eandlymph node status.
Carcinomas were considered to be oestrogen receptor positive
if at least 10% of tumour cells showed nuclear reactivity.
Information regarding oestrogen receptor status was available for
99 carcinomas. There was a relationship between cyclin E levels
and oestrogen receptor status (X2 = 3.94, 1 d.f., 0.05 > P > 0.025),
oestrogen receptor-positive tumours having a higher incidence of
no or low levels ofcyclin Eexpression.
A significant relationship existed between cyclin E expression
and theproliferation index (x2 =25.87, 2d.f., P <0.001), such that
a high expression of cyclin E was associated with a high MIB1
index. A total of 5 ofthe 31 carcinomaspositive forcyclin Ehad a
low MIB 1 score, three with 5% positive cells and two with
40-50% positive cells. The other cases withhighcyclin Estaining
all had high MIB 1 indices. A correlation was also found between
the presence of p53 protein and 5% > cells positive for cyclin E
(%2 = 4.96, 1 d.f., 0.05 > P> 0.025). Ten ofthe 11 carcinomas that
had bothp53 andcyclin E werepoorlydifferentiated, as were 70%
of those tumours with 5% > of cells positive for cyclin Ebut p53
negative. For those cases that werep53positive butnegative or low
forcyclin E, half werepoorly differentiated.
DISCUSSION
Knowledge of the aberrant expression of the cell cycle regulatory
proteins in breast cancer may increase information about the
biological nature ofthe disease and may be useful inpredicting the
prognosis of individual breast carcinomas. It may also be one of
the factors which determines why prognosis varies considerably
from woman to woman.
Altered regulation of the cell cycle may be a very early change
in the development of breast carcinomas as it would allow cells
with damaged DNA to divide, thus replicating unrepaired muta-
tions. There is no clear understanding of the natural history of
breast cancer, but women with proliferative lesions, particularly
atypical forms, are at higher risk of developing breast cancer
(Dupont andPage, 1985), which suggests that alteredregulation of
cell proliferation may occur at an early stage. The approach we
have used is to study non-involved tissue from cancer containing
breasts to determine whether alteredcyclin Eexpression can occur
in morphologically normal tissue. This is clearly important as
Alpers and Wellings (1985) suggested that factors promoting the
development of breast carcinoma have a 'field effect'. However,
the lack ofcyclin E immunoreactivity in this tissue suggests that
alterations to the cyclin Eprotein either do not occur as a field
change in breast cancer, or do not result in increased expression at
this stage.
Ductal carcinoma in situ(DCIS) is apreinvasive lesion which, if
left, may progress to an invasive carcinoma (Lagios, 1990).
Therefore, we investigated cyclin E expression in the different
histological subtypes of DCIS, particularly as this has not been
addressed in previous studies. Although limited by the small
sample size, it is obvious thatcyclin E was detectable in a propor-
tion (9 out of 22) of the in situ lesions. In particular, one high-
grade tumour showed approximately 35% nuclearstaining. These
(preliminary) results suggest that alterations to cyclin E occur at
relatively early stages in a proportion ofbreast cancers.
Overexpression of cyclin E has been observed in 10 out of 10
breast cancer cell lines and breast tissue using Western blotting tech-
niques (Keyomarsi and Pardee, 1993; Keyomarsi et al, 1994; Nielsen
et al, 1996). It has been suggested that deregulation ofcyclin E may
be a factor contributing to the malignant phenotype (Keyomarsi and
Pardee, 1993; Keyomarsi et al, 1994; Dutta et al, 1995). Recently,
Western blotting of 114 breast tumour specimens showed that
women with tumours with high cyclin E levels had a significantly
increased risk ofdeath and relapse from breast cancer (Nielsen et al,
1996). Keyomarsi et al (1994) also showed that the alterations in
cyclin Eexpression became greater with increasing grade and stage
(Keyomarsi et al, 1994). However, no studies have examined similar
numbers of invasive carcinomas using immunohistochemistry and
correlated the findings to clinicopathological parameters.
Immunohistochemical staining with a monoclonal antibody
reveals the proportion of individual tumour cells in which protein
can be detected. The frequency of cyclin E expression may be
underestimated in studies utilizing Western blotting techniques,
because of the heterogeneity and presence of non-cancerous cells
in the sample and varied amounts ofextracellular stromal proteins.
However, the percentage ofcarcinomas considered to have greater
reactivity was very similar to that found by Nielsen et al (1996).
Immunohistochemistry revealed that 23 out of 109 (21%) carci-
nomas exhibited no nuclear cyclin E at all, and were therefore
similar to non-malignant breast. Keyomarsi and Pardee (1994)
noted that cyclin E could be detected at very low levels in
homogenates of normal and cancerous breast using immunoblot-
ting. It is therefore probable that immunohistochemistry is unable
to detect normal cyclin E in the nucleus as a result of its low
expression. As a consequence, the nuclear reactivity, when
detected in malignancies, is likely to be due to cyclin Eisotypes
and/or normal cyclin E, which are both stabilized and remain as
active complexes throughout the cell cycle. It is interesting that
mRNAs coding for these cyclin E isoforms have been found in
both normal breast tissue and tumour, but the protein isoforms
are tumour specific, suggesting post-transcriptional and/or post-
translational regulation ofcyclin E (Keyomarsi et al, 1995).
In this study, expression ofcyclin Ein more than 5% of tumour
cells correlated significantly with poor tumour grade, which
was in agreement with previous studies using immunoblotting
(Keyomarsi et al, 1994; Nielsen et al, 1996). In addition, cyclin E
expression was significantly associated with a high proliferation
fraction, which had previously been demonstrated in the immuno-
histochemical study by Dutta et al (1995). Dutta et al identified a
small fraction of tumours that overexpressed cyclin E relative to
proliferation. There were two carcinomas identified with high
cyclin E reactivity but low proliferation, which could suggest
deregulated cyclin Eexpression. It is unclear whether overexpres-
sion ofcyclin Ein the breast tissue is the result of, or the cause of,
cellular proliferation. Evidence for the latter comes from the
studies ofKeyomarsi et al (1995), who demonstrated that cyclin E
isotypes remain in an active complex with cdk2. They also showed
that the protein isotypes in this active complex were capable of
phosphorylating substrates such as histone 1. There are clearly
other factors involved in determining proliferation because in the
present study carcinomas were identified with high proliferation
indices but with little or no detectable cyclin E.
Carcinomas that were oestrogen receptor positive were more
likely to have no detectable cyclin E or low levels of detection,
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which correlates with the findings for differentiation and prolifera-
tion. It contrasts with cyclin Dl, the other important G, cyclin,
whose overexpression is known to correlate with the presence of
oestrogen receptor (Gillet et al, 1996). A relationship was also
found between p53 and cyclin E but this may be indirect as virtu-
ally all the carcinomas with p53 protein and cyclin E were poorly
differentiated. Data were not available to determine whether the
immunoreactive p53 protein was due to mutation or stabilization
by other factors. Although strong associations between mutation
and staining have been reported (Gretarsdottir et al, 1996), it is
evident from this study that false positives and negatives occur.
There was insufficient follow-up data beyond 12-24 months for
the group of carcinomas studied so it was not possible to assess
whether cyclin E, as determined by immunohistochemistry, can
provide similar prognostic information to that obtained from
immunoblotting studies (Nielson et al, 1996). However, careful
analysis would be needed to examine whether it would be an
independent marker, in view of the strong association we have
found with poor differentation and high proliferation.
The mechanisms underlying the expression ofcyclin E in breast
carcinomas have yet to be defined. It is not known whether there is
gene amplification, stabilization of mRNA or altered transcrip-
tional regulation, and whether there is a specific abnormality or
whether expression is due to altered proliferation. Static studies,
such as the present one, will not be able to answer these questions,
but this study does demonstrate that cyclin E expression is associ-
ated with poorer differentiation, lack of oestrogen receptor and
higher proliferation and may identify a group ofcarcinomas with a
poorer behaviour and different therapeutic responses.
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